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Abstract
Background data: Chordomas are the most common sacral tumors, usually treated by wide resections with free
margins. Radical resections are likely followed by signiﬁcant neurological deﬁcits that may not be accepted for some
patients who present with preserved neural functions.
Purpose: To present a local institutional experience in the technique and outcome of subtotal sacrectomy followed by
maximally tolerated radiation therapy in a cohort of patients having high sacral (S1eS2) chordomas who presented with
intact neurological functions and were not previously treated.
Study design: This is a retrospective case series.
Patients and methods: This is a retrospective case series conducted over 7 years, including 14 consecutive patients with
high-level sacral chordomas who refused radical resection and underwent subtotal sacrectomy aiming to preserve as
many neural structures as possible, followed by three-dimensional conformal radiotherapy given at a maximum dose
tolerated by the surrounding viscera. The surgical resection, perioperative management, including radiotherapy techniques, and their functional and oncologic outcomes were reviewed.
Results: The mean age was 44.6 ± 4.7 years, and 10 (71.4%) cases were males. Patients complained of sacral pain for 2e9
months before diagnosis, and all were continent with no gross sensorimotor deﬁcits. Resections were performed through
posterior-only approaches using T-shaped or inverted U-shaped incisions. Surgeries went uneventful, with two incisions
indicated for further plastic management. Negative margins were achieved in one case. Bladder/bowel functions were
lost postoperatively in 28.6% of cases. Ten cases had disease progression at a mean duration of 62.4 ± 27.9 months. The
median survival was 99 months. The 5-year absolute survival rate was 78.6% and the 5-year disease progression was
42.9%. The overall survival in this study was found to be 35.7%, with a median follow-up of 6.3 years.
Conclusion: Despite the promising outcomes at 5 years, the used strategy was associated with sphincteric dysfunctions
in a substantial proportion of patients and failed to achieve an adequate overall survival. We recommend radical
resections for young patients to improve survival. Subtotal sacrectomy followed by three-dimensional conformal radiation can be a valid alternative for older patients with shorter life expectancy (2021ESJ250).
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Introduction

Patient selection and preoperative assessment

C

The medical records of patients admitted
between November 2008 and December 2015 into
the Departments of Neurosurgery and Surgical
Oncology with the diagnosis of sacrococcygeal lesions were revised on June 2021 (date of data
collection). All histopathologically conﬁrmed
chordomas presented at high levels reaching
S1eS2 segments were included as potential candidates. This histologic diagnosis was established
postoperatively in most cases because only some
surgeons performed a preoperative ﬁne-needle
trucut biopsy. Cases that received initial management (surgery or irradiation) elsewhere were
excluded. Moreover, cases approved to perform
radical (R0) resections were excluded from the
study. Exclusion criteria implemented for ﬁnal
eligibility are presented in Table 1.
All selected cases had signed ‘informed refusal’
forms declining radical sacrectomy because of the
inevitable postoperative sensorimotor/sphincteric
deﬁcits. Patients also signed informed consent
accepting the likely recurrence and possible need
for redo surgeries. Records of neurological examination, laboratory investigations, and radiologic
assessments, including metastatic workup, were
reviewed. All cases were treated with rectal enemas
and surgical areas were shaved, followed by a
shower using povidone-iodine shampoo in the night
before surgery. Intravenous antibiotics were
administered within 60 min from the surgical incision. An indwelling urinary catheter was inserted
routinely for continuous bladder drainage after
induction of anesthesia.

hordoma is a locally malignant, slowly
growing tumor of the midline axial skeleton
arising from remnants of the notochord and representing 1e4% of primary bone tumors [1]. However,
it is the most frequently encountered primary
malignant neoplasm of the sacral region [2], which
usually presents late owing to its slow course and
subtle symptoms [3]. Such tumors used to be
considered not susceptible to radiotherapy or
chemotherapy [4], with en bloc resection including
free margins regarded as the standard care of
management to prevent recurrence and tumor
progression [5]. However, in high sacral chordomas
reaching S2 or higher, total sacrectomy with free
margins can result in 100% bowel/bladder
dysfunction and lost plantar ﬂexion, necessitating
ankle orthosis in up to 40% of cases [6]. In circumstances when the likely postoperative deﬁcits are
not accepted by the patient, subtotal sacrectomy
may be an alternative surgical strategy with the
drawback of a higher possibility of recurrence [7].
The evidence of radiotherapy has been established
for sacral chordoma in the cases of marginal (R1)
and intralesional (R2) surgical resection as a complementary treatment [8]. Conﬁrmatory studies and
analyses revealed that there is no survival beneﬁt of
adding external beam radiation therapy to negative
surgical margin, while improved survival rates were
conﬁrmed by adding high doses of RT more than
65 Gy and proton beam therapy [9,10] and using
carbon ion therapy [11] and intensity-modulated
radiation therapy [12].
Many reports in the literature discussing chordomas have represented heterogeneous cohorts of
patients, including primary and secondary lesions,
affecting different spinal locations, treated via
diverse modalities, various surgical techniques, and
unequal radiation doses, making outcome measures
uninterpretable [4,13e23].
This study aimed to present local experience in
subtotal sacrectomy provided to patients with sacral
chordoma who presented with intact neurological
functions and did not accept radical resections for
the sake of neurological integrity. We also present
functional and oncologic outcomes over the followup period.

Patients and methods
This is a retrospective case series including consecutive high-level sacral chordoma cases that underwent
subtotal sacrectomy followed by three-dimensional
(3D) conformal radiotherapy over a period of ~7 years.

Table 1. Eligibility criteria for the study group.
Cases

Numbers

Total cases with sacral lesions
presented over 9 years
Conﬁrmed sacral chordomas not
previously treated elsewhere
Excluded cases
Cases of low chordomas (below S2)
Cases presented with
sensorimotor deﬁcits
Cases considered inoperable
(with distant metastasis)
Cases refused any form of
surgical intervention
Cases accepted radical
sacrectomy despite
predicted neurological and
sphincteric affection
Eligible cases with neural-preserving
sacrectomy for high sacral chordomas

84
41

15
5
2
2
3
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Preoperative planning
With the help of the neuroradiologist, the pelvic
computed tomography (CT) scan with 3D reconstruction views and the lumbosacral MRI were
reviewed. Although the tumor was not visible in 3D
CT views, these images were important to check for
the sacroiliac joint integrity and the details of the
bony surface of the sacrum. Bone osteotomy lines in
coronal and sagittal planes were designed and
correlated to the bony surface details and
surrounding landmarks to guide intraoperative
bone cutting. According to right/left and anterior/
posterior deferential extensions of the tumor, the
obliquity of coronal and sagittal cuts was determined, respectively. All osteotomy lines were
intended not to extend proximal to S1/S2 interface
to avoid injuring proximal sacral roots contributing
to ankle movements, sensations, and sphincteric
functions. Tumor portions extending proximal to
osteotomy lines were evaluated intraoperatively for
possible debulking or marginal resections.
Surgical technique
All cases received hypotensive general anesthesia
for better hemostasis and underwent an operation
in a prone position with ﬂexed hips and knees.
Intraoperative ﬂuoroscopy was not used in any of
the cases. The skin was prepared and draped from
the level of the last rib to the middle of the intergluteal cleft. Two types of surgical incisions were
performed by operating surgeons as per revised
records (Fig. 1). A wide inverted U-shaped skin
incision was performed in six cases with its two
limbs extending into the middle of each buttock
down to the coccyx level, while its dome is located
just below the intercrestal line. A full-thickness skin
ﬂap based distally was then raised with the help of
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monopolar electrocautery to expose the region of
the sacrum and sacroiliac joints. In eight cases (with
preoperative Trucut biopsy), T-shaped skin
incisions were performed with the vertical limb
extending from above the intergluteal cleft in the
midline up to the L5/S1 level and the transverse
limb extending in a curvilinear manner between the
upper margins of both sacroiliac joints. The vertical
limb of the incision was planned to include the tract
of trucut biopsy allowing for tract excision during
the operation to avoid the risk of tract seeding by the
tumor.
After elevating the skin and subcutaneous tissues, the lumbosacral facia was elevated bilaterally
from its spinous attachments and divided transversely on each side to expose the sacrum and
lamina of L5. Subsequent steps were similar in all
cases, starting with bilateral identiﬁcation and division of the medial attachments of the gluteus
maximus and the sacrotuberous ligaments with a 2cm safety margin. The piriformis muscle was then
identiﬁed and divided together with sacrospinous
and sacrococcygeal ligaments to enter the retroperitoneal space bilaterally. At that point, blunt
dissection using a dry gauze was started to separate
the soft tissues anterior to the sacrum without
breaching the tumor pseudocapsule until the
anterior tissues were separated completely distally
to proximally. An abdominal towel gauze was then
passed anteriorly to the sacrum to protect retroperitoneal structures.
Laminectomy L5 and the removal of posterior
sacral elements were then performed to expose the
thecal sac down to the level of S3 roots. The second
sacral roots were preserved in all cases. However, S3
roots were assessed carefully for functionality and
extent of being involved by the tumor. Unilateral S3
resection was decided in 10 patients (eight on the

Fig. 1. Types of skin incisions and exposure provided by them. On the left is the inverted U-shaped skin incision. On the right is the modiﬁed Tshaped incision.
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right and two on the left side), whereas bilateral
resection was performed in four cases. The unequal
extension of the tumor bilaterally allowed for the
preservation of single S3 roots in most patients. All
sacriﬁced roots were extensively inﬁltrated and
seemed nonfunctioning for the operating surgeon.
The thecal sac was then ligated and divided below
the level of neural preservation to expose the posterior sacral surface.
Any tumor extension to the ala of the sacrum or
parts of sacroiliac joints or ilium was removed
using a rongeur, leaving healthy bone without
violating more than one-third of the sacroiliac
joints. Sacral osteotomy was carried out through
normal bone proximal to the upper extension of
the tumor with the abdominal towel keeping the
retroperitoneal structures safe. During osteotomy,
proximal and distal to-and-fro movements of the
hand carrying the osteotome helped the surgeon
estimate the completion of bone cutting until the
sacrum was fully mobilized. The anococcygeal
ligament was then divided to free the distal end,
which was elevated posteriorly and upward using
Allis tissue forceps to expose the underlying
space. Careful separation of the sacral piece was
done by separating any residual attachments
under direct visual control to ﬁnalize tumor
extraction (Fig. 2).
None of our cases were indicated for spinal or
spinopelvic stabilization. The posterior pelvic repair
was performed using polypropylene mesh to support the rectum and avoid a future sacral hernia,
followed by tight closure of the overlying facia if not
invaded by the tumor (Fig. 3).
Protocol of postoperative management
Patients passed their postoperative stay in a regular ward with drains in place for the ﬁrst 48e72 h.

Urinary catheters were removed the next postoperative day to evaluate spontaneous voiding.
Catheters were reinserted again in cases unable to
pass urine. Only the prone and lateral positions
were allowed by operating surgeons for the ﬁrst few
days to a week. Daily dressings were done once for
dry wounds and at least twice when signiﬁcant
soaking was noticed. During the postoperative
period, prophylaxis against deep venous thrombosis
was conducted, including good hydration and mechanical and pharmacological measures. A pneumatic intermittent compression device was used
when available (nine cases) from day 1 after surgery.
Alternatively, above-knee compression, elastic
stockings (ﬁve cases) were applied with regular
manual massages to calves thrice daily. Enoxaparin
sodium 40 mg subcutaneously once per day was
started 12 h after surgery in all patients until
achieving full mobilization. On the 10th to 12th day
postoperatively, sutures were removed in dry
healed wounds. Ambulation was allowed when
tolerated with the aid of a four-legged adjustable
walking frame. Cases with wound issues were
managed in combination with plastic surgery.
Radiotherapy technique
All resected cases were referred to adjunctive
radiotherapy once the healing of their wounds was
complete. Planning of all patients was done using a
CT simulator with CT cuts at 5-mm intervals to the
whole pelvis after ordinary setup measures of the
patients. Eye fusion was used with MRI pelvis slides
to ensure the exact delineation of the gross target
volume (GTV) of any residual soft tissue at the
operative bed. Then, the clinical target volume,
deﬁned as the preoperative tumor size, was then
delineated, as shown in the preoperative CT ﬁlms.
Finally, the planned target volume is generated by

Fig. 2. (A) The use of abdominal towel gauze for gentle gradual separation of the tumor. (B) Final appearance of the ﬁeld following sacrectomy with
the ligated thecal sac just distal to last preserved roots and posterior wall of the rectum. (C) The excised tumor after maximum possible safe resection.
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Fig. 3. Posterior pelvic repair was performed using polypropylene mesh (to the left side) to support the rectum and avoid a future sacral hernia,
followed by tight closure of the overlying facia (to the right side), giving further support to the posterior rectal wall.

adding a 10-mm homogenous margin to the clinical
target volume.
The main limiting factors from increasing the dose
beyond 60 Gy were the absence of the intensitymodulated radiation therapy technique in our
institute and the dose constraints in surrounding
organs at risk, namely, the bladder and rectum. The
tolerance dose for the bladder and rectum is 60 Gy
and for the ‘intestines’ is 45 Gy. All of the cases were
positioned prone and treated with a three-ﬁeld
technique; planned target volume received a 60-Gy
total dose, whereas the GTV may reach up to
105e109% of the dose (i.e. 63e65 Gy); this dose was
our limit, as we could not reach beyond 60 Gy to the
organs at risk.
Follow-up and outcome assessment
Follow-up schedules were given to the patients,
including regular and emergency visits. Regular
visits to the outpatient clinic were 2 weeks after
discharge, every 3 months during the ﬁrst year,
every 6 months during the second year, and then
annually afterward. Emergency visits were indicated in case of swelling, local pain, or neurological
deﬁcits. Data collected during follow-up visits
included local, neurological, and radiographic
examinations of the chest and pelvis. A detailed CT
scan was performed for all cases postoperatively
and in selected situations during follow-up (Fig. 4).
MRI was performed postoperatively, then every 6
months during the ﬁrst 2 years, and annually afterward, in addition to any time disease progression

was suspected by the attending physician (Fig. 4). At
the time of data collection, telephone calls for
selected patients (i.e. dropouts) were performed
with the preparation of a visit to the clinic when
possible to complete follow-up data. The duration of
follow-up was estimated as the time between diagnosis and the end of follow-up, which was either the
time of data collection or the time of death. Death in
this study was either due to disease progression
(died of disease) or unrelated events (died from
other causes). Functional outcome was evaluated at
the end of the second year of follow-up and the end
of follow-up according to Karnofsky performance
status [24]. Oncologic outcome was determined by
median overall survival (OS), 5-year absolute survival rate, progression-free survival (PFS) rate at 2
years, and 5-year disease progression. The median
OS was calculated using the KaplaneMeier method
and was deﬁned as the length of time from the date
of diagnosis that half of the patients with chordoma
were still alive (Fig. 5). PFS rate at 2 years was
deﬁned as the percentage of patients at the end of
the second year postoperatively without signs of
tumor progression. Five-year absolute survival rate
was the percentage of patients alive 5 years from
diagnosis, whereas 5-year disease progression was
the percentage of patients with conﬁrmed local
progression at 5 years from diagnosis. Tumor progression was estimated by revising the documented
MRI data immediately after surgery and during the
follow-up period. Residual tumors in early postoperative MRIs were classiﬁed as either sizable
(with reported longest diameter in MRI 10 mm) or
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Fig. 4. A case of S1/S2-coccyx chordoma. (A) sagittal MRI showing the homogenous hyperintense tumor reaching proximally to S1eS2 level. (B)
coronal MRI showing more extent of the tumor to the left. (C) Preoperative 3D pelvic CT scan with planned osteotomy designed (red line). (D) Early
postoperative lumbosacral CT ‘sagittal reformat,’ revealing the level of resection and laminectomy levels. (E) Axial postoperative CT, showing the
preservation of sacroiliac joints. (F) Postoperative 3D pelvic CT showing the extent of osteotomy and preservation of upper three sacral foramina on
the right side (red arrows). (G) Six-month postoperative MRI with contrast with no residual lesion. (H) One-year postoperative MRI with contrast
revealing no evidence of disease (NED). (I) Two-year lumbosacral MRI with contrast indicating NED. CT, computed tomography.

nonsizable (longest diameter <10 mm or not detected). Progression for sizable residuals was deﬁned
as an estimated increase of more than or equal to
20% (from MRI-reported dimensions) in the longest
diameter of the lesion or in the sum of the longest

diameters of two or more lesions during the followup. Progression of nonsizable lesions was deﬁned as
an MRI-conﬁrmed appearance of one or more new
lesions and/or unequivocal progression of a nonsizable preexisting lesion. These parameters were
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Fig. 5. A case of S1-coccyx chordoma. (A) Sagittal MRI showing proximal, distal, anterior, and posterior extents of the tumor. (B) Axial MRI shows
the differential extent of the tumor to the right side. (C) The excised sacral specimen showing an asymmetrical shape of the specimen. (D) Postoperative 3D pelvic CT, showing the oblique osteotomy line, which was more proximal on the right to accommodate the tumor extension. CT,
computed tomography.

guided by the RECIST criteria introduced in 2000 to
assess changes in tumor burden in response to
therapy [25]. Lesions that became invisible in
follow-up MRI were considered complete remission, whereas those that remained detectable but
did not fulﬁl criteria of progression were considered
stable local residuals.

Results

some sphincteric disturbances, though they
remained stool/urine continent. All cases presented
with sacral pain lasting from 2 to 9 months (median
of 4.4 months and interquartile range of 4) before
diagnosis. Clinical presentations, patient characteristics, and tumor characteristics are presented in
Table 2. In the six cases with some sphincteric disturbances, the lesion affected lower S1, whereas in
other cases, lesions reached up to S1 or S2.

Demographics and clinical characteristics

Operative results and complications

The current study included 14 cases of high sacral
chordomas reaching S2 or higher that were continent
with no gross sensorimotor deﬁcits and underwent
subtotal sacrectomy followed by maximally tolerated
local radiotherapy. Their ages ranged from 38 to 51
years, with a mean of 44.6 ± 4.7 years. Ten (71.4%)
cases were males, with a male to female ratio of 5 : 2.
None of the selected patients had sensorimotor deficits preoperatively; however, six (43%) patients had

The osteotomy level was done at nearly S1eS2
junction in all cases after exposure of the spinal
canal widely and preserving as many as possible of
the intact sacral roots. The osteotomy lines were
designed as oblique as needed to accommodate the
asymmetrical tumor extension bilaterally (Fig. 5). All
surgical procedures were uneventful, with no reported visceral or vascular injuries. The mean blood
loss was about 1441 ± 410 ml, as calculated by
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Table 2. Demographic and clinical criteria with maximum documented follow-up period.
Case

Age

Sex

Presentation (duration/month)

Tumor extent

Largest
diameter/cm

Tumor location

1
2
3
4
5
6
7
8
9
10
11
12
13
14

49
42
49
39
50
38
51
46
47
42
39
47
38
47

F
M
M
M
M
F
F
M
M
M
M
F
M
M

Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia
Sacralgia

S1-Coccyx
S2eS4
S2eS5
S2eS5
S1eS5
S1-Coccyx
S1eS5
S2-Coccyx
S1eS4
S1-Coccyx
S2eS4
S2eS5
S2eS4
S1-Coccyx

11.4
9.2
7.9
10.1
11.3
10.2
12.0
9.6
11.4
9.8
8.6
9.5
11.6
12.3

Presacral-postsacral
Presacral
Presacral-postsacral
Presacral
Presacral
Presacral
Presacral-postsacral
Presacral
Presacral
Presacral-postsacral
Presacral
Presacral-postsacral
Presacral
Presacral-postsacral

(5) and frequency of micturition (2)
(7) and saddle paresthesia (2)
(3) and sacral swelling (0.5)
(4)
(6) and frequency of micturition (1)
(4) and saddle paresthesia (3)
(2), sacral swelling (0.5), and poor stream (0.7)
(6) and saddle paresthesia (1)
(8) and straining to void (2.2)
(2) and hesitancy of micturition (1.3)
(4)
(7)
(9) and saddle paresthesia (2)
(3) and straining to void (2),

F, female; M, male; S1eS5, sacral pieces 1e5.

summing up the blood volume collected from the
reservoir of the suction device and that estimated in
soaked surgical gauzes and towels.
Two patients developed wound dehiscence during
the postoperative hospital stay with no cerebrospinal ﬂuid leak and were referred to plastic care for
ﬂap procedures. One of them had a T-shaped skin
incision with ischemic gapped corners of the
wound, whereas the other had a U-shaped incision
and developed wound infection and delayed healing. The latter was diabetic for more than 10 years.
The two patients underwent successful management by plastic surgeons with complete healing
within 3e4 weeks. Other patients were discharged
with clean, dry wounds 1e2 days following suture
removal. Patients received radiation therapy 4e6
weeks after complete surgical wound healing.

There were no reported venous thromboembolic
events during the postoperative hospital stay or in
follow-up visits. The results of pathological examination of surgical margins, bladder/bowel control
after surgery, and the 2-year functional and oncologic outcomes are presented in Table 3. All cases
were of the chondroid chordoma subtype. Negative
margins of excised specimens were histopathologically documented in only one (7%) case. In 71.4% of
cases, bladder and bowel control could be preserved
and remained so over 2 years of follow-up.
Outcome results
By the end of the second year of follow-up, most
cases (about 71%) were able to carry on normal
activity and work with some signs or symptoms of

Table 3. Margins and outcomes at 2 years.
Cases

Margins

Bladder and bowel functions

KPS

Disease status

1
2
3
4
5

Positive
Positive
Positive
Positive
Positive

100
80
90
90
70

Stable local residual
Complete remission
Stable local residual
Stable local residual
Stable local residual

6
7
8
9

Positive
Positive
Positive
Positive

90
100
100
70

Stable local residual
Complete remission
Complete remission
Stable local residual

10
11

Positive
Positive

90
60

Stable local residual
Local progression

12
13
14

Negative
Positive
Positive

Normal
Normal
Normal
Normal
Intermittent catheterization,
digital rectal evacuation
Normal
Normal
Normal
Intermittent catheterization,
digital rectal evacuation
Normal
Intermittent catheterization,
digital rectal evacuation
Normal
Normal
Intermittent catheterization,
repeated enemas

90
80
60

Complete remission
Stable local residual
Local progression

KPS, Karnofsky performance scale.
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the disease, whereas nearly 29% of cases were unable to work but could live independently at home
and care for most of their personal needs. The median Karnofsky performance status was 90 (60e100)
and 70 (0e100) at 2 and 5 years, respectively. The
mean follow-up duration was 77.2 ± 23.1 months.
Ten (71.4%) cases had disease progression at a
mean duration of 62.4 ± 27.9 months. The time of
recurrence and ﬁnal status at the end of follow-up
are presented in Table 4. Two (14%) cases had a
conﬁrmed local disease progression before 2 years,
and two cases developed metastasis with delayed
progression (at 50 and 54 months) of initially stable
residuals. The cases with early disease progression
(<2 years) had postoperative residuals after
maximal safe resections with the largest diameters
of about 3.2 and 2.5 cm within the S1 vertebra, which
could not be excised without sacriﬁcing neural (S1
and S2 roots) functions. At the time of progression,
these tumors were 5.3 and 4.1 cm, respectively. Both
cases underwent salvage palliative management
after informed consent, in the form of debulking
surgery with an additional dose of 18 Gy over 10
fractions targeting the GTV ‘tumor recurrence’ with
a 10-mm margin. One of these two cases died at 34
months, whereas the other survived but developed a
very poor functional outcome at 5 years and died
shortly after. The other eight cases with later disease
progression refused further resections. Six of them
were referred to palliative radiotherapy for pain
control, putting into consideration the previous dose
received (60 Gy) and the time gap. The other two
cases decided to perform further surgical management elsewhere.
Overall, 86% of cases remained stable or underwent remission at 2 years postoperatively (2 year-
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PFS rate, 86%). The median OS was 99 months
(SE ¼ 20.8, 95% conﬁdence interval ¼ 58.1e139.8) as
measured by the KaplaneMeier curve (Fig. 6). The
5-year absolute survival rate was estimated to be
78.6%. Six cases developed disease progression
either locally or distally or both with/without death
from the disease by 5 years (i.e. 42.9% 5-year disease
progression).

Discussion
Although chordomas have been long considered a
radioresistant tumor, radiotherapy was reported to
be a useful modality when used adjunctively to
surgery but not adequate as a freestanding therapy
[26,27]. Although some authors have reported no
survival beneﬁts for postoperative radiation therapy
[15], their patients received radiation doses between
25 and 60 Gy. This contrasts with our patients, who
all received high doses of at least 60 Gy. Others [27],
found that the addition of radiation therapy in
subtotal resections can prolong the median time to
recurrence from 8 months to 2.12 years. The authors
have reported a PFS rate of 86% at 2 years in the
current study. Similarly, some authors suggested
that preoperative or postoperative irradiation permits marginal resection in high sacral chordomas
allowing for neural function preservation [26].
Although the mean age and the median duration
of symptoms were comparable to other recent reports [28], earlier studies have reported older ages
and longer duration of symptoms [13,29]. This may
be owing to the inclusion of smaller tumors at lower
sacral levels rendering symptoms vaguer with late
urinary symptoms. Males were almost double the
females (5 : 2), which was close to other reports

Table 4. Recurrence/progression and outcome at 5 years and ﬁnal status.
Case

DOF (months)

Recurrence/local
progression (TAT/month)

KPS at 5 years

Final status

1
2
3
4
5
6
7
8
9
10
11
12
13
14

99
102
56
118
51
63
97
91
86
77
61
75
71
34

Positive (79)
Positive (92)
Positive (54)
Positive (108)
Positive (50)
Positive (57)
Negative, stable residual
Negative, complete remission
Positive (81)
Positive (58)
Positive (23)
Negative, complete remission
Negative, stable residual
Positive (22)

70
80
0
90
0
70
100
100
70
80
20
100
70
0

DOD
DOD
DOD
DOD
DOD
DOD
LWD
DOC
LWD
LWD
DOD
NED
LWD
DOD

DOC, dead from other causes; DOD, dead of disease; DOF, duration of follow-up; KPS, Karnofsky performance scale; LWD, living with
disease; NED, no evidence of disease; TAT, time after treatment.
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Fig. 6. KaplaneMeier curve, revealing the median overall survival of 99 months (SE ¼ 20.8, 95% conﬁdence interval ¼ 58.1e139.8).

[13,29e31]. According to Wei et al. [32], the tumors
in our study were of types II and III. A combined
anterioreposterior resection is recommended for
these types when they are big tumors extending
above the S1 level, whereas posterior-only resection
is preserved for smaller tumors at lower levels [32].
All of our cases were operated via a posterior-only
approach using inverted U-shaped or modiﬁed Tshaped incisions. The former seemed simpler,
allowing wider exposure with comparable healing,
whereas the latter was more suitable in cases with
preoperative biopsy allowing for excision of the
track of biopsy during surgery.
All surgeries went uneventful, with acceptable
blood loss compared with other studies [28,30]. All
cases retained gross sensorimotor functions as S2
roots were preserved in all. However, bladder/bowel
functions could be retained in only 71% of cases.
Four cases (with bilateral S3 root sectioning) lost their
bladder/bowel control postoperatively. Previous
studies have reported the importance of S3 roots in
bladder/bowel functions. Todd et al. [33] have reported that bilateral preservation of S3 roots was
associated with retained bowel/bladder functions in
100 and 69% of cases, whereas unilateral preservation resulted in retained functions in 67 and 60%,
respectively. Another study reported that the S3 root
was primarily involved in bladder contraction with
predominance for the right side [34]. The predominant concentration of B ﬁbers within the S3 root,
representing the parasympathetic nerves that control
bladder functions [35], may explain preserved
sphincteric functions in cases with saved S3 roots.
With improvement in radiation technology,
effective higher doses can now be safely delivered to

residual or inoperable sacral chordomas with minimal toxic effects on nearby tissues [17,20,23,36,37].
In a recent study, therapeutic RT was associated
with a signiﬁcant prolongation of the OS in the case
of positive surgical margins that were found to be
close to that of patients with negative margins. The
authors suggested that surgical excision with planned positive margins and postoperative therapeutic
RT is an acceptable strategy to reduce surgical
sequelae [9]. All of the patients managed in the
current study received high-dose postoperative radiation therapy with the 3D conformal technique,
respecting dose constraints to surrounding tissues
with no reported radiation-related complications
during the follow-up period.
Most of the chordoma studies in the literature are
very heterogenous, including chordomas of
different locations, using various modalities of
management and studying heterogeneous cohorts
of primary and secondary chordomas. Surgery
alone, proton/photon/carbon ions therapy, and
surgery ± preoperative/postoperative photon therapy were all reported in the literature
[4,5,11,12,14,16,18,19,21,22,38e44]. On the contrary,
this study included a homogenous subgroup of patients. The authors found the 5-year survival rate to
be comparable to some studies [11,12,16] but far
below the others [4,19]. PFS at 5 years was 57.1%
among our patients, which was comparable to the
results from some studies [9,22] but inferior to the
results of other studies [4,45]. In an analytic study
exploring the prognostic factors affecting the survival of primary chordomas, they found age more
than or equal to 60 years, distant metastasis, and
nonsurgical therapy to be predictors of reduced
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survival [46]. In another study comparing prognostic
factors for primary and secondary sacral chordomas, not receiving radiation was found to be an
independent predictor for worse local PFS [45]. The
relatively young age of our patients and the early
presentation might have a positive effect on the 5year outcome. However, the OS in this study was
found to be 35.7%, with a median follow-up of 6.3
years, where 28.6% (4/14) were living with the disease and 7.1% (1/14) had no evidence of the disease.
This survival rate is considered signiﬁcantly shorter
compared with several studies reporting 52e84%
survival at 10 years [5,22,39e41]. This was because
21.4% of patients died before 5 years, whereas 42.9%
died between 5 and 10 years with a resulting loss of
survival beneﬁt after 5 years.
The authors believe that these survival results are
inferior and not adequate for young patients who
are otherwise healthy with a long expectancy of life.
Although subtotal sacrectomy followed by 3D
conformal radiation saved motor and sensory
functions of operated patients, this strategy resulted
in 28.6% loss of bladder/bowel functions owing to
inadvertent root injuries, making it not a completely
safe technique. For these reasons, it is believed that
wide (R0) surgical resection with a secondary goal of
neural preservation in young patients who presented to medical care with high sacral chordomas
and neural integrity is a more appropriate management in favor of longer survival. Preoperative
trucut biopsy for establishing the diagnosis should
be implemented in all patients as it was proved to be
a safe procedure with no additional risk of seeding
of the tract when adequately excised through
appropriately planned incisions. In addition, preoperative tissue diagnosis helps educate the patient
about the nature of the disease and the likely
outcome following marginal and intralesional resections, including multiple recurrences, repeated
surgeries, and ultimately loss of function and thus
can reduce rejections of radical surgeries. On the
contrary, older patients with comorbidities and
shorter life expectancy may gain beneﬁt from the
relatively good 5-year survival of the used strategy
having the advantage of neural preservation.
One of the limitations of the current study is the
limited sample size, making it exposed to type II
error. Second is the retrospective nature of the
study. However, the selection of a subgroup of a
relatively rare pathology to explore the outcome of
their management is a hard task to perform prospectively. Third, no control group was available to
compare the oncologic outcomes of radical free
margin sacral resection with conservative high sacrectomy combined with postoperative high-dose
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radiation therapy. Finally, the lack of more
advanced radiotherapy techniques, especially intensity-modulated radiation therapy or stereotactic
RT, would enable delivering doses beyond 60 Gy to
the GTV that may reach up to 75 Gy without
increasing toxicity and give us more local control.

Conclusion
Despite the promising outcomes at 5 years, the
used strategy was associated with sphincteric dysfunctions in a substantial proportion of patients and
failed to achieve an adequate OS. We recommend
radical resections for young patients to improve
survival. Subtotal sacrectomy followed by 3D
conformal radiation can be a valid alternative for
older cases with shorter life expectancy.

Ethical statements
This study is done following the the World Medical Association Declaration of Helsinki, as a statement for ethical principles for medical research.All
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with research consent to publish the medical data.
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ﺍﻟﻤﻠﺨﺺ ﺍﻟﻌﺮﺑﻲ

ﺍﻻﺳﺘﺌﺼﺎﻝ ﺍﻟﺠﺰﺋﻲ ﻟﻠﻌﺠﺰ ﻣﺘﺒﻮﻋﺎ ﺑﺎﻹﺷﻌﺎﻉ ﺍﻟﻤﻄﺎﺑﻖ ﺛﻼﺛﻲ ﺍﻷﺑﻌﺎﺩ ﺑﺠﺮﻋﺎﺕ ﺍﻹﻃﺎﻗﺔ ﺍﻟﻘﺼﻮﻯ ﻟﻌﻼﺝ ﺣﺎﻻﺕ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺤﺒﻠﻴﺔ ﺍﻟﻌﺠﺰﻳﺔ ﺍﻟﻌﻠﻴﺎ ﺫﺍﺕ ﺍﻟﺴﻼﻣﺔ ﺍﻟﻌﺼﺒﻴﺔ :ﺍﻟﺘﻘﻨﻴﺎﺕ ﻭ ﺍﻟﻨﺘﺎﺋﺞ

ﺍﻟﺒﻴﺎﻧﺎﺕ ﺍﻟﺨﻠﻔﻴﺔ
ﺍﻟﻬﺪﻑ

ﺍﻟﺴﻠﻴﻤﺔ

ﺗﻌﺘﺒﺮ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺤﺒﻠﻴﺔ ﺃﻛﺜﺮ ﺍﻷﻭﺭﺍﻡ ﺍﻟﻌﺠﺰﻳﺔ ﺷﻴﻮﻋﺎ ﻭ ﺗﺤﺘﺎﺝ ﺍﺳﺘﺌﺼﺎﻝ ﺟﺮﺍﺣﻲ ﺫﻭ ﺣﻮﺍﻑ ﺣﺮﺓ ﻭ ﺍﻟﺬﻱ ﻗﺪ ﻳﺆﺩﻱ ﺇﻟﻰ ﺇﺻﺎﺑﺎﺕ ﻋﺼﺒﻴﺔ ﻓﻲ ﺑﻌﺾ ﺍﻟﻤﺮﺿﻰ

ﻋﺮﺽ ﺍﻟﺨﺒﺮﺓ ﺍﻟﺠﺮﺍﺣﻴﺔ ﻭ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﻤﺘﺮﺗﺒﺔ ﻋﻠﻰ ﺍﻟﺠﺮﺍﺣﺎﺕ ﺍﻟﺘﺤﻔﻈﻴﺔ ﺍﻟﻌﺼﺒﻴﺔ ﺍﻟﻤﺘﺒﻮﻋﺔ ﺑﺎﻟﻤﻌﺎﻟﺠﺔ ﺍﻹﺷﻌﺎﻋﻴﺔ ﻟﻤﺮﺿﻰ ﺍﻷﻭﺭﺍﻡ ﺍﻟﺤﺒﻠﻴﺔ ﺍﻟﻌﺠﺰﻳﺔ ﺫﻭﻱ ﺍﻟﻮﻇﺎﺋﻒ ﺍﻟﻌﺼﺒﻴﺔ

ﺗﺼﻤﻴﻢ ﺍﻟﺪﺭﺍﺳﺔ

ﺩﺭﺍﺳﺔ ﺣﺎﻟﺔ ﺗﺴﻠﺴﻠﻴﺔ ﺍﺳﺘﻌﺎﺩﻳﺔ

ﺍﻟﻤﺮﺿﻰ ﻭ ﺍﻟﻄﺮﻕ ﺷﻤﻠﺖ ﺍﻟﺪﺭﺍﺳﺔ  ١٤ﺣﺎﻟﺔ ﺃﻭﺭﺍﻡ ﺣﺒﻠﻴﺔ ﻋﺠﺰﻳﺔ ﻋﻠﻴﺎ ﺃﺟﺮﻳﺖ ﻟﻬﺎ ﺟﺮﺍﺣﺎﺕ ﺗﺤﻔﻈﻴﺔ ﻋﺼﺒﻴﺔ ﻣﺘﺒﻮﻋﺔ ﺑﻤﻌﺎﻟﺠﺔ ﺇﺷﻌﺎﻋﻴﺔ ﺛﻼﺛﻴﺔ ﺍﻷﺑﻌﺎﺩ ﺧﻼﻝ  ٧ﺳﻨﻮﺍﺕ .ﺗﻢ
ﻣﺮﺍﺟﻌﺔ ﺍﻹﺟﺮﺍﺀﺍﺕ ﺍﻟﺠﺮﺍﺣﻴﺔ ﻭ ﺍﻟﻌﻼﺟﻴﺔ ﻭ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﻮﻇﻴﻔﻴﺔ ﻭ ﺍﻟﻮﺭﻣﻴﺔ
ﺍﻟﻨﺘﺎﺋﺞ ﺑﻠﻎ ﻣﺘﻮﺳﻂ ﺍﻷﻋﻤﺎﺭ  ٤٤،٦ﺳﻨﻮﺍﺕ ﻣﻊ ﻏﺎﻟﺒﻴﺔ ﺫﻛﻮﺭﻳﺔ .ﻋﺎﻧﻰ ﺍﻟﻤﺮﺿﻰ ﻣﻦ ﺁﻻﻡ ﻋﺠﺰﻳﺔ ﻟﻤﺪﺓ  ٢ﺇﻟﻰ  ٩ﺃﺷﻬﺮ ﻗﺒﻞ ﺍﻟﺘﺸﺨﻴﺺ ﺩﻭﻥ ﺇﺻﺎﺑﺎﺕ ﻋﺼﺒﻴﺔ ﺃﻭ ﺳﻠﺲ ﺍﻟﻤﺼ ّﺮﺓ .ﻟﻢ
ﻳﻮﺟﺪ ﻣﻀﺎﻋﻔﺎﺕ ﺟﺮﺍﺣﻴﺔ ﺑﺎﺳﺘﺜﻨﺎﺀ ﺟﺮﻭﺡ ﺣﺎﻟﺘﻴﻦ ﺗﻢ ﻋﻼﺟﻬﻤﺎ ﺗﺠﻤﻴﻠﻴﺎ .ﺑﻠﻐﺖ ﻧﺴﺒﺔ ﺷﻠﻞ ﺍﻟﻤﺼ ّﺮﺓ ﺑﻌﺪ ﺍﻟﺠﺮﺍﺣﺔ  ٪٢٨،٦ﻣﻦ ﺍﻟﺤﺎﻻﺕ .ﺗﻔﺎﻗﻢ ﺍﻟﻤﺮﺽ ﻓﻲ  ١٠ﺣﺎﻻﺕ ﺑﻌﺪ ﻣﺘﻮﺳﻂ ٦٢،٤
.ﺷﻬﺮ ﻣﻦ ﺍﻟﻤﺘﺎﺑﻌﺔ .ﺑﻠﻎ ﻣﺘﻮﺳﻂ ﺍﻟﺒﻘﺎﺀ  ٩٩ﺷﻬﺮ ،ﺑﻴﻨﻤﺎ ﺑﻠﻐﺖ ﻧﺴﺒﺔ ﺍﻟﺘﻔﺎﻗﻢ ﺧﻼﻝ  ٥ﺳﻨﻮﺍﺕ  .٪٤٢،٩ﻛﺎﻧﺖ ﻧﺴﺒﺔ ﺍﻟﺒﻘﺎﺀ ﺍﻟﻌﺎﻡ  ٪٣٥،٧ﻋﻨﺪ ﻣﺘﻮﺳﻂ ﻣﺘﺎﺑﻌﺔ  ٦،٣ﻋﺎﻡ
ﺍﻟﺨﻼﺻﻪ ﺭﻏﻢ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﻮﺍﻋﺪﺓ ﻋﻨﺪ  ٥ﺳﻨﻮﺍﺕ ﻟﻺﺟﺮﺍﺀ ﺍﻟﻌﻼﺟﻲ ﻣﺤﻞ ﺍﻟﺒﺤﺚ ،ﺇﻻ ﺃﻥ ﺍﻟﻨﺘﺎﺋﺞ ﺍﻟﻤﺘﻌﻠﻘﺔ ﺑﻮﻇﺎﺋﻒ ﺍﻟﻤﺼ ّﺮﺓ ﻭ ﻧﺴﺒﺔ ﺍﻟﺒﻘﺎﺀ ﺍﻟﻌﺎﻡ ﻛﺎﻧﺖ ﻏﻴﺮ ﻣﺮﺿﻴﺔ ﺑﻘﺪﺭ ﻳﺠﻌﻞ ﺫﻟﻚ
.ﺍﻹﺟﺮﺍﺀ ﺍﻟﻌﻼﺟﻲ ﻏﻴﺮ ﻣﺜﺎﻟﻲ ﻟﺼﻐﺎﺭ ﺍﻟﺴﻦ ﻭ ﻳﻤﻜﻦ ﺗﻄﺒﻴﻘﻪ ﻟﺤﺎﻻﺕ ﻣﺨﺘﺎﺭﺓ ﻣﻦ ﺫﻭﻱ ﺍﻷﻋﻤﺎﺭ ﺍﻟﻤﺘﻘﺪﻣﺔ

